Increasing Demand For Solid Dosage Form In The Healthcare Industry Is Propeling The Market For Superdisintegrants Continue To Rise

The global Superdisintegrants Market is expected to reach USD 487.0 million by 2025, according to a new report by Grand View Research, Inc. Superdisintegrants help in the disintegration of tablet or capsule content into small particles and create a greater surface area for speedy drug release.

us-superdisintegrants-market.png

A number of fast disintegrating tablet such as salbutamol sulphate, and cetirizine hydrochloride in tablet/capsule dosage form for respiratory disorders (bronchitis, asthma, and coughing) are formulated for pediatric and geriatric patients, due to their difficulty or discomfort in swallowing. Superdisintegrant such as crospovidone, croscarmellose sodium, and sodium starch glycolate are used in optimized concentration to formulate such tablets/capsules along with different binders such as MCC and PVP K-30.

Access Full Research Report on Superdisintegrants Market: http://www.grandviewresearch.com/industry-analysis/superdisintegrants-market

Further key findings from the study suggest:

  • The market study suggests that crospovidone dominated the overall market in 2016. Crospovidone is completely insoluble in water and rapidly disperses and swells in water.  It has greatest rate of swelling and surface area to volume ratio compared to other disintegrants. Hence, these factors are contributing towards the large share of crospovidone in 2016.
  • Others segment, which includes natural superdisintegrants, is expected to witness highest growth rate. Factors such as local accessibility, bio-acceptable, renewable source, eco‐friendly nature and lower prices compared to important synthetic products, are driving the growth of the segment during the forecast period.
  • Amongst the dosage form segments, tablets and capsules occupied the largest share in 2016 as they are the most common and preferred dosage forms for delivering drugs to patients.
  • The mouth-dissolving films segment is expected to grow at the highest growth rate during the forecast period. It is the preferred choice for patients as compared to tablets and capsules due to greater flexibility and comfort of the former.
  • Hence, the market for disintegrants in mouth-dissolving films would continue to grow due to quicker onset of action for a dosage form and better convenience of administration.
  • North America dominated the regional segment with the largest revenue share in 2016, due to number of superdisintegrants manufacturers operating in the region and prolific research and development initiatives
  • Asia Pacific is expected to witness significant growth during the forecast period, owing to booming medical tourism industry in the region and lucrative contract research outsourcing services
  • Some of the major companies operating in this market are Ashland Global Holdings Inc., Roquette Frères S.A., FMC Corporation, DFE Pharma, Huber Corporation, Nippon Soda Co., Ltd. The Dow Chemical Company and BASF SE. and others.

Read Our Blog: http://www.grandviewresearch.com/blog/superdisintegrants-market-developing-fast-dissolving-tablets

Grand View Research has segmented the superdisintegrants market on the basis of product, dosage form, and region:

Product Outlook (Revenue, USD Million, 2014 – 2025)

  • Croscarmellose sodium
  • Crospovidone
  • Sodium starch glycolate
  • Ion exchange resin
  • Others

Dosage Form Outlook (Revenue, USD Million, 2014 – 2025)

  • Tablets and Capsules
  • Mouth-dissolving Films

Regional Outlook (Revenue, USD Million, 2014 – 2025)

  • North America
    • US.
    • Canada
  • Europe
    • Germany
    • UK
  • Asia Pacific
    • China
    • Japan
  • Latin America
    • Brazil
    • Mexico
  • MEA
    • South Africa

View Press Release of this Report: http://www.grandviewresearch.com/press-release/global-superdisintegrants-market

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For More Information: www.grandviewresearch.com

Advertisements

Superdisintegrants Market Is Anticipated To Witness A Rapid Growth, Increasing At A CAGR Of Over 7.2% From 2014 To 2025

The global Superdisintegrants Market is expected to reach USD 487.0 million by 2025, according to a new report by Grand View Research, Inc. Superdisintegrants help in the disintegration of tablet or capsule content into small particles and create a greater surface area for speedy drug release.

us-superdisintegrants-market.png

A number of fast disintegrating tablet such as salbutamol sulphate, and cetirizine hydrochloride in tablet/capsule dosage form for respiratory disorders (bronchitis, asthma, and coughing) are formulated for pediatric and geriatric patients, due to their difficulty or discomfort in swallowing. Superdisintegrant such as crospovidone, croscarmellose sodium, and sodium starch glycolate are used in optimized concentration to formulate such tablets/capsules along with different binders such as MCC and PVP K-30.

Access Free Report On Superdisintegrants Market: http://www.grandviewresearch.com/industry-analysis/superdisintegrants-market

Further key findings from the study suggest:

  • The market study suggests that crospovidone dominated the overall market in 2016. Crospovidone is completely insoluble in water and rapidly disperses and swells in water.  It has greatest rate of swelling and surface area to volume ratio compared to other disintegrants. Hence, these factors are contributing towards the large share of crospovidone in 2016.
  • Others segment, which includes natural superdisintegrants, is expected to witness highest growth rate. Factors such as local accessibility, bio-acceptable, renewable source, eco‐friendly nature and lower prices compared to important synthetic products, are driving the growth of the segment during the forecast period.
  • Amongst the dosage form segments, tablets and capsules occupied the largest share in 2016 as they are the most common and preferred dosage forms for delivering drugs to patients.
  • The mouth-dissolving films segment is expected to grow at the highest growth rate during the forecast period. It is the preferred choice for patients as compared to tablets and capsules due to greater flexibility and comfort of the former.
  • Hence, the market for disintegrants in mouth-dissolving films would continue to grow due to quicker onset of action for a dosage form and better convenience of administration.
  • North America dominated the regional segment with the largest revenue share in 2016, due to number of superdisintegrants manufacturers operating in the region and prolific research and development initiatives
  • Asia Pacific is expected to witness significant growth during the forecast period, owing to booming medical tourism industry in the region and lucrative contract research outsourcing services
  • Some of the major companies operating in this market are Ashland Global Holdings Inc., Roquette Frères S.A., FMC Corporation, DFE Pharma, Huber Corporation, Nippon Soda Co., Ltd. The Dow Chemical Company and BASF SE. and others.

Grand View Research has segmented the superdisintegrants market on the basis of product, dosage form, and region:

Product Outlook (Revenue, USD Million, 2014 – 2025)

  • Croscarmellose sodium
  • Crospovidone
  • Sodium starch glycolate
  • Ion exchange resin
  • Others

Dosage Form Outlook (Revenue, USD Million, 2014 – 2025)

  • Tablets and Capsules
  • Mouth-dissolving Films

Regional Outlook (Revenue, USD Million, 2014 – 2025)

  • North America
    • US.
    • Canada
  • Europe
    • Germany
    • UK
  • Asia Pacific
    • China
    • Japan
  • Latin America
    • Brazil
    • Mexico
  • MEA
    • South Africa

Browse Press Release of this Report: http://www.grandviewresearch.com/press-release/global-superdisintegrants-market

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For More Information: www.grandviewresearch.com

Recent Emerging Trends in Healthcare Sector will have positive impact on growth of Clinical Trial Supplies Market

The global Clinical Trial Supplies Market is expected to reach USD 3.3 billion by 2025, according to a new report by Grand View Research, Inc. The market is expected to witness growth at 7.3% CAGR owing to Increasing volume of clinical trial studies coupled with the growing complexity in conduction of these trials are the primary driver of the industry. Furthermore, geographic expansion and development of Information Technology (IT) to facilitate higher integration and smooth performance of activities are other vitally impacting parameters. Over the next eight years, the clinical trials and pharmaceutical industry is anticipated to continue steady growth, thereby promoting the high requirement of clinical trial supplies.

us-clinical-trial-supplies-market.png

U.S and Canada are home to majority of clinical trials which are conducted in this region. No language barrier is one of the major factor for the preference of this region for majority of clinical trials, as English language is widely spoken in this region. Major CRO’s and biopharmaceutical companies have their hub in this region and with advancement in technology the demand for efficient supplies are increasing and the region is expected to dominate the clinical trial supplies market over the forecast period.

Browse Full Research Report on Clinical Trial Supplies Market: http://www.grandviewresearch.com/industry-analysis/clinical-trial-supplies-market

Further Key Findings From the Study Suggest:

  • On the basis of clinical phase, the market is anticipated to be dominated by Phase III in 2025. The presence of large number of molecule estimated to reach Phase III by 2020 is the primary factor responsible for this prediction.
  • By services, storage and distribution is anticipated to witness the fastest growth at a CAGR of over 7.0%.
  • Key end-users of this industry are pharmaceuticals, and biologics. Biologics are expected to witness fastest growth owing to the increasing research in the field of genetics and biotechnology such as development of nanoparticle based drug delivery systems.
  • In terms of therapeutic use or clinical indication, oncology dominates the market. The highest research activity as of 2016 is being performed for this indication, which in turn is expected to drive the market.
  • Few of the industry players include Movianto GmbH, Thermo Fischer Scientific, Sharp Packaging Services, Catalent Pharma Solution, Biocair International Ltd., PCI Services, Almac Group Ltd, and Patheon Inc. Other players present in the market space include Clinigen Group Plc, Merck Serono, and Chimerix.

Read Our Blog: http://www.grandviewresearch.com/blogs/healthcare

Grand View Research has segmented the clinical trial supplies market by phase, product/service, end-use, therapeutic use and region:

Clinical Phase Outlook (Revenue, USD Million; 2014 – 2025)

  • Phase I
  • Phase II
  • Phase III
  • Others

Product/Service Outlook (Revenue, USD Million; 2014 – 2025)

  • Manufacturing
  • Storage & distribution
    • Cold chain based
    • Non-cold chain based
  • Supply chain management

End-Use Outlook (Revenue, USD Million; 2014 – 2025)

  • Pharmaceuticals
  • Biologics
  • Medical device
  • Others

Therapeutic Use Outlook (Revenue, USD Million; 2014 – 2025)

  • Oncology
  • CNS
  • Cardiovascular
  • Infectious disease
  • Metabolic disorders
  • Others

Regional Outlook (Revenue, USD Million; 2014 – 2025)

  • North America
    • US.
    • Canada
  • Europe
    • Germany
    • UK
  • Asia Pacific
    • China
    • Japan
  • Latin America
    • Mexico
    • Brazil
  • MEA
    • South Africa
    • Saudi Arabia

Browse Press Release of this Report: http://www.grandviewresearch.com/press-release/global-clinical-trial-supplies-market

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For More Information: www.grandviewresearch.com

Hemophilia Market is Poised To Reach $15.2 Billion By 2024: Grand View Research, Inc.

The Global hemophilia market is expected to reach USD 15.2 billion by 2024, according to a new report by Grand View Research, Inc. Increasing need for diagnosis of the target population in order to initiate prophylaxis treatment and supportive government programs is expected to be the vital impact rendering driver.

hemophilia-treatment-industry.png

The market players are predicted to adopt strategies such as pipeline product development and geographic expansion in underdeveloped and developing regions, such as Middle Eastern and West African countries.

As of 2015, federal bodies such as the World Federation Hemophilia have vast information and treatment regulation in about 172 countries, of which 20 were added in 2013,including Nigeria, Togo, Mali, Zambia, Mauritania, and others.

Competitive pricing strategy is a vital factor promoting market players’ growth over the forecast period. For instance, Biogen launched Eloctate in 2014 in the U.S. at a lower price than the existing vastly used drug Advate.

Browse Full Research Report on Hemophilia Market: http://www.grandviewresearch.com/industry-analysis/hemophilia-treatment-industry

Further Key Findings From the Study Suggest:

  • Hemophilia B is expected to grow at a rapid rate of over 6.0% during the forecast period. Higher emphasis on pipeline products with an extended half-life and increasing incidence of hemophilia B affected patients are expected to be the prominent growth factors.
  • On-demand treatment dominated the segment over the forecast period and is expected to contribute more than 50.0% by 2024. However, prophylaxis is expected to be the fastest growing segment because of the requirement for better control of bleeding episodes and growing financial assistance programs by healthcare providers and industry players.
  • For instance, Grifols has launched the “AlphaNine SD Copay Card” and “ALPHANATE Copay Program” for immediate enrollment in prophylaxis treatment by patients.
  • On the basis of therapy, gene therapy is expected to be the fastest growing segment as a result of increasing R&D and innovations in the field. Furthermore, replacement therapy is expected to witness lucrative growth due to the launch of extended half-life versions of currently available drugs.
  • For instance, Novo Nordisk is working on N8-GP, CSL Behring is working on CSL689 rVIIa-FP, and Bayer is working on BAY 94-9027.These are expected to be commercially available around 2017/2018. This is expected to improve treatment over the forecast period thereby boosting growth.
  • Major market players include Biogen, Novo Nordisk, Baxalta, Octapharma, CSL Behring, Pfizer, Inc., and Bayer Healthcare. Most of the companies are actively involved in the awareness and treatment programs launched by regional governments and hemophilia associations. Majority of their products that are awaiting FDA approval have extended therapeutic use in adults as well as children.

Read Our Blog: http://www.grandviewresearch.com/blogs/healthcare

Grand View Research has segmented the global hemophilia market on the basis of type, treatment, therapy, and region.

Global Hemophilia Market by Type (USD Million), 2013 – 2024

  • Hemophilia A
  • Hemophilia B
  • Hemophilia C
  • Others

Global Hemophilia Market by Treatment (USD Million), 2013 – 2024

  • On-demand
  • Prophylaxis

Global Hemophilia Market Therapy(USD Million), 2013 – 2024

  • Replacement Therapy
  • Immune Tolerance Induction Therapy
  • Gene Therapy

Hemophilia Market By Region (USD Million), 2013 – 2024

  • North America
    • US.
    • Canada
  • Europe
    • UK
    • Germany
  • Asia-Pacific
    • Japan
    • China
  • Latin America
    • Brazil
    • Mexico
  • Middle East and Africa
    • South Africa
    • Saudi Arabia

Browse Press Release of this Report: http://www.grandviewresearch.com/press-release/global-hemophilia-market

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For More Information: www.grandviewresearch.com

Surge in Elderly Population & Rise in chronic diseases is Key factors driving of Enteral Feeding Formulas Market Growth

The global enteral feeding formulas market is expected to reach over USD 7.5 billion by 2024, according to a new report by Grand View Research, Inc. Key factors driving growth include increase in geriatric population, rise in chronic diseases, rising preterm births, and increasing demand for home care services.

enteral-feeding-formulas-market

The enteral feeding formulas market is expected to witness lucrative growth over the forecast period, owing to a few benefits such as the preservation of gastrointestinal tract structure and its functioning, low-cost alternative to support the patient nutrition, and lowering of rate of infection.

According to the WHO, an estimated 15 million babies are born prematurely, which accounts for 1 in every 10 babies. Furthermore, nearly 1 million children die every year due to complications of preterm birth. The growing nutritional requirements for neonates, infants, and children are boosting the consumption of various enteral feeding products. Moreover, the children suffering from chronic disease conditions and severe malnutrition are expected to drive the use of specialized formulas over the forecast period.

Increase in aging population will have a major impact on the enteral feeding formulas market. The ageing population requires more focus to treat chronic diseases like osteoporosis, heart disease, Alzheimer’s disease, and others. According to Administration on Ageing, it is estimated that approximately 80% of people aged 65 and above have at least one chronic illness; as a result, the usage of various enteral feeding formulas is expected to grow rapidly over the forecast period.

Browse Full Research Report On Enteral Feeding Formulas Market: http://www.grandviewresearch.com/industry-analysis/enteral-feeding-formulas-market

Further Key Findings from the Study Suggest:

  • In 2015, standard formulas dominated the enteral feeding formulas market with a revenue share of over 64.3%. The use of standard formulas from many years is one of the key reasons for the high share. However, the disease-specific formulas segment is expected to have the highest CAGR of 8.6%. The healthcare providers prefer the use of disease-specific formulas to tackle the disease-based nutritional deficiencies in pediatric and adult patients.
  • The oncology segment accounted for the maximum share of over 36% in 2015. The diabetic segment is expected to be the fastest growing application with a CAGR of 8.4% over the forecast period.
  • North America accounted for the majority share of over 38%, due to growing disease burden, increase in geriatric population, growing number of surgical procedures, increasing awareness about nutritional supplements, and well-developed healthcare networks
  • Some key players operating in the market are Abbott Laboratories, Nestle S.A, Danone S.A, Fresenius Kabi AG, B. Braun Melsungen AG, Mead Johnson & Company, LLC. These players face intense competition and therefore, these companies leverage their brand value and sales channel network to increase their market share.

Read Our Blog: http://www.grandviewresearch.com/blogs/healthcare

Grand View Research has segmented the enteral feeding formulas into type, stage, application, end use and region.

Enteral Feeding Formulas Market, by Product (USD Million, 2015 – 2024)

  • Standard Formulas
  • Disease Specific formulas

Enteral Feeding Formulas Market, by Stage (USD Million, 2015 – 2024)

  • Adults
  • Pediatric

Enteral feeding Formulas Market, by Application (USD Million, 2015 – 2024)

  • Oncology
  • Gastroenterology
  • Neurology
  • Diabetes
  • Critical care

Enteral Feeding Formulas Market, by End User (USD Million, 2015 – 2024)

  • Hospitals
  • Long-term care
  • Homecare

Enteral Feeding Formulas Market, by Region, (USD Million, 2012 – 2024)

  • North America
    • US.
    • Canada
  • Europe
    • Germany
    • UK
  • Asia Pacific
    • Japan
    • China
  • Latin America
    • Brazil
    • Mexico
  • MEA
    • South Africa

Browse Press Release of this Report: http://www.grandviewresearch.com/press-release/global-enteral-feeding-formulas-market

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For More Information: www.grandviewresearch.com

Increasing Incidence of Chronic Diseases Is Expected To Accelerate Erythropoietin Drugs Market Growth Pace Substantially

The global Erythropoietin (EPO) Drugs Market is expected to reach USD 17.4 billion by 2025, according to a new report by Grand View Research, Inc. Rising incidence of chronic diseases such as CKD and cancer resulting in anemia is a major growth driver of this market.

According to the statistics published by the National Heart, Lung, and Blood Institute of the U.S. Department of Health & Human Services, over 3 million people are affected by anemia every year and this number is expected to increase over the forecast period. This showcases the need for erythropoietin-stimulating agents in the coming years.

us-erythropoietin-epo-drugs-market.png

Introduction of novel drugs and their cheaper biosimilar formulations with enhanced efficacy and cost-effectiveness is also expected to serve this industry with lucrative opportunities. For instance, development of numerous biosimilars in the European market is expected to gain traction and increase their usage rates, owing to associated benefits such as less time required for approval, cost-efficiency, and enhanced therapeutic effect.

Companies are involved in extensive R&D initiatives for development of innovative molecules and discovering new therapeutic areas for existing drugs. For instance, in April 2016, Sandoz received approval from the European Commission for use of its biosimilar Binocrit in nephrology indications, thereby extending the therapeutic area of its product portfolio.

Moreover, many of the industry players in the U.S., Europe, and Asia Pacific are involved in the development of new biosimilars. For example, Biocon’s subsidiary Syngene International entered into an agreement with Bristol-Myers Squibb to extend their drug discovery and development program in India. This enables Biocon to enhance its erythropoietin drugs portfolio. Expected product approvals in the coming years are anticipated to fuel market growth.

Browse Full Research Report on Erythropoietin Drugs Market: http://www.grandviewresearch.com/industry-analysis/erythropoietin-epo-drugs-market

Further key findings from the study suggest:

  • The biologics segment is declining over the forecast period owing to patent expiration of branded biologics and introduction of biosimilars in the market
  • The patent for Aranesp (darbepoetin-alfa) will expire in 2024 in the U.S. and is expected to provide numerous future growth opportunities for new market entrants
  • Epoetin-alfa held the largest share of product segment owing to its early introduction in the U.S. market and patent protection
  • Epoetin-omega and epoetin-zeta are anticipated to exhibit lucrative growth over the forecast period owing to associated benefits such as longer half-life and enhanced therapeutic effects
  • Use of erythropoietin drugs for treatment of renal diseases held a dominant share as of 2016 owing to the increasing incidence of chronic kidney diseases
  • The Asia Pacific regional industry for erythropoietin-stimulating agents is expected to witness lucrative CAGR during the forecast period
  • Industry participants are focusing on the discovery of new therapeutic areas for existing drugs and development of cost-effective biosimilars, thereby increasing R&D activities for the development of erythropoietin drugs.

Read Our Blog: http://www.grandviewresearch.com/blogs/healthcare

Grand View Research has segmented the erythropoietin (EPO) drugs market on the basis of the drug class, product, application, and region:

Erythropoietin Drugs Drug class Outlook (Revenue, USD Million, 2014 – 2025)

  • Biologics
  • Biosimilar

Erythropoietin Drugs Product Outlook (Revenue, USD Million, 2014 – 2025)

  • Epoetin-alfa
  • Epoetin-beta
  • Darbepoetin-alfa
  • Others

Erythropoietin Drugs Application Outlook (Revenue, USD Million, 2014 – 2025)

  • Cancer
  • Hematology
  • Renal Diseases
  • Neurology

Erythropoietin Drugs Regional Outlook (Revenue, USD Million, 2014 – 2025)

  • North America
    • US.
    • Canada
  • Europe
    • Germany
    • UK
  • Asia Pacific
    • Japan
    • China
    • India
  • Latin America
    • Brazil
    • Mexico
  • MEA
    • South Africa

Browse Press Release of this Report: http://www.grandviewresearch.com/press-release/global-erythropoietin-epo-drugs-market

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For More Information: www.grandviewresearch.com

Industry Expert Predict Quick Growth for Global Pharmaceutical Packaging Market through forecast period

The global Pharmaceutical Packaging Market is expected to reach USD 158.8 billion by 2025, according to a new report by Grand View Research, Inc. The growing demand for pharmaceuticals coupled with increased emphasis on product packaging is expected to drive market growth.

germany-pharmaceutical-packaging-market.png

Pharmaceutical packaging market comprises wide array of products. The demand for these products is expected to grow rapidly on account of fortification of medicines and drugs against exterior impacts. However, the packaging materials and products need to bear the brunt of stringent government regulations and growing market for counterfeit pharmaceuticals. Counterfeit pharmaceuticals are expected to pose a major threat to manufacturers.

North America is a dominant region in the market backed by thriving pharmaceutical industry and rapid new product introduction. Asia Pacific is anticipated to grow rapidly on account of rising pharmaceutical manufacturing in China and India. The growing trend of contract packaging in the pharmaceutical industry is expected to further augment market growth in Asia Pacific.

Browse Full Research Report on Pharmaceutical Packaging Market: http://www.grandviewresearch.com/industry-analysis/pharmaceutical-packaging-market

Further key findings from the report suggest:

  • Aluminum foil material segment is projected to grow at a CAGR of 7.2% from 2017 to 2025 owing to rising demand for packaging of special purpose drugs.
  • Paper and paperboard is the second largest product segment and is expected to reach USD 40.83 billion by 2025 due to growing demand in secondary packaging products.
  • Blister packs in the primary pharmaceutical packaging product category is expected to grow at a CAGR of 9.2% from 2017 to 2025 on account of growing demand in oral drugs.
  • The market share of Asia Pacific is expected to reach 33% in 2025 owing to growing demand for pharmaceuticals and presence of large number of plastic manufacturers
  • The Middle East & Africa region is expected to grow at a CAGR of 5.6% from 2017 to 2025 backed by growing demand for medicines in Tanzania, Nigeria and South Africa.
  • The market is highly dispersed due to the presence of a large number of small and large manufacturers

Read Our Blog: http://www.grandviewresearch.com/blogs/healthcare

Grand View Research has segmented the global pharmaceutical packaging market on the basis of material, product, end-use and region:

Pharmaceutical Packaging Material Outlook (Revenue, USD Billion, 2014 – 2025)

  • Plastics & Polymers
  • Paper & Paperboard
  • Glass
  • Aluminum Foil
  • Others

Pharmaceutical Packaging Product Outlook (Revenue, USD Billion, 2014 – 2025)

  • Primary Packaging
  • Secondary Packaging
  • Tertiary Packaging

Pharmaceutical Packaging End-use Outlook (Revenue, USD Billion, 2014 – 2025)

  • Pharmaceutical Manufacturing
  • Contract Packaging
  • Retail Pharmacy
  • Institutional Pharmacy
  • Others

Pharmaceutical Packaging Regional Outlook (Revenue, USD Billion, 2014 – 2025)

  • North America
  • Europe
  • Asia Pacific
  • Central & South Africa
  • Middle East & Africa

Access press release of this research report by Grand View Research: http://www.grandviewresearch.com/press-release/global-pharmaceutical-packaging-market

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For More Information: www.grandviewresearch.com